Clinical trials: Opioid Induced Constipation (OIC)
Cancer, Constipation
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
The purpose of this study is to determine if naloxegol can be used in the treatment of opioid-induced constipation in patients with cancer and pain.
- Conditions
- Cancer, Constipation, Pain
- Trial name
- NCT02839889
- Testing
- Naloxegol
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Hospice of Henderson County, Inc.
Constipation, Analgesia
Enteral Naloxone Versus a Traditional Bowel Regimen for the Prevention of Opioid Induced Constipation in Trauma Patients
The purpose of this study is to determine if enteral naloxone is more effective than a traditional bowel regimen in the prevention and treatment of constipation and impaired gastric motility in critically ill trauma patients.
- Trial name
- NCT00799201
- Testing
- Naloxone and Docusate
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- CAMC Health System
Opioid-Induced Constipation
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
The purpose of this study is to evaluate the safety and efficacy of CB-5945 for the treatment of opioid-induced constipation (OIC) in adults taking opioid therapy for chronic non-cancer pain.
- Trial name
- NCT01901302
- Testing
- CB-5945
- Volunteers
- 61 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Constipation, Impaction, and Bowel Obstruction, Unspecified Adult Solid Tumor, Protocol Specific
Naloxone in Treating Constipation in Patients Who Are Receiving Opioids for Chronic Pain
RATIONALE: Naloxone may be effective in treating constipation that may be caused by opioid pain medications such as morphine. PURPOSE: Phase III trial to determine the effectiveness of naloxone in relieving constiption in…
- Trial name
- NCT00020605
- Testing
- naloxone hydrochloride
- Where
- United States
- Sponsor
- Dana-Farber Cancer Institute
Opioid Use, Constipation Drug Induced
Study on Quality of Life in Advanced Cancer Patients With Opioid-induced Constipation Treated With Naloxegol
Opioid-Induced Constipation (OIC) is often associated with a compromised quality of life of patients in palliative care (PC) setting.
- Conditions
- Opioid Use, Constipation Drug Induced, Cancer
- Trial name
- NCT04294550
- Testing
- Naloxegol
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Fondazione ANT Franco Pannuti ETS
Opioid-induced Constipation, Cancer
Study of Opioid-Induced Constipation 1 Project
The aim of the project is to investigate opioid-induced constipation (OIC) in a real world / diverse group of patients with cancer.
- Conditions
- Opioid-induced Constipation, Cancer, Cancer Pain
- Trial name
- StOIC-1 (NCT04350112)
- Testing
- Clinical assessment
- Where
- 16 sites in United Kingdom
- Volunteers
- 1,007 people
- Sponsor
- Royal Surrey County Hospital NHS Foundation Trust
Opioid Induced Constipation
Naloxegol US PMR CV Safety.
The overall research goal for this study is to provide additional data to characterize the safety of naloxegol in patients aged 18 years and older who do not have a diagnosis of cancer and who are treated with opioids chronically
- Trial name
- NCT02813356
- Testing
- naloxegol, non-PAMORA
- Where
- 2 sites in United States
- Volunteers
- 8,800 people
- Sponsor
- Valinor Pharma LLC
Opioid-induced Constipation, Cancer
Study of Opioid-Induced Constipation 2 Project
The aim of the project is to investigate OIC in a real world / diverse group of patients with cancer. The objectives of the project are to determine: a) efficacy of a treatment algorithm to manage OIC; b) efficacy of conventional…
- Conditions
- Opioid-induced Constipation, Cancer, Cancer Pain
- Trial name
- StOIC-2 (NCT04404933)
- Testing
- Treatment algorithm for OIC
- Where
- 16 sites in United Kingdom
- Volunteers
- 100 people
- Sponsor
- Royal Surrey County Hospital NHS Foundation Trust
Opioid-Induced Constipation (OIC)
Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
The purpose of this study is to evaluate the effect and safety of NKTR-118 treatment of opioid-induced constipation in patients with non-cancer-related pain, including those patients that have inadequate response to laxative…
- Trial name
- NCT01309841
- Testing
- NKTR-118
- Where
- 117 sites in United States, Australia and 2 more
- Volunteers
- 652 people
- Sponsor
- AstraZeneca
Patients With Opioid Induced Constipation
Longitudinal Study of Patients With Opioid-Induced Constipation
This prospective hybrid longitudinal study was conducted in the United States (US), Canada, the United Kingdom (UK), and Germany.
- Trial name
- NCT01928953
- Where
- 30 sites in United States, Canada
- Volunteers
- 520 people
- Sponsor
- AstraZeneca
Opioid-induced Bowel Dysfunction
Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)
The primary purpose of the study is to evaluate the efficacy and safety of lubiprostone administration in subjects with Opioid-induced Bowel Dysfunction.
- Trial name
- NCT01298219
- Testing
- Lubiprostone
- Where
- 142 sites in United States, Belgium and 5 more
- Volunteers
- 439 people
- Sponsor
- Sucampo Pharma Americas, LLC
Chronic Pain
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
The study will be investigating the effectiveness of oxycodone-naloxone (brand name Targin®) at treating chronic pain in individuals with spinal cord injury.
- Trial name
- NCT03179475
- Testing
- Oxycodone Naloxone Combination
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- University of British Columbia
Constipation
Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain
The primary purpose of the protocol is to evaluate the safety, efficacy, and tolerability of subcutaneous MOA-728 versus placebo in subjects with chronic non-malignant pain who have Opioid-Induced Constipation (OIC).
- Trial name
- NCT00529087
- Testing
- N-methylnaltrexone bromide (MOA-728)
- Where
- 78 sites in United States
- Volunteers
- 460 people
- Sponsor
- Bausch Health Americas, Inc.
Low Back Pain
Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain
The primary objective is to assess the efficacy of oxycodone/naloxone (OXN) for the management of opioid-induced constipation (OIC) compared to oxycodone controlled-release tablets (OXY) in subjects with moderate to severe low…
- Trial name
- NCT01427270
- Testing
- Oxycodone/Naloxone controlled-release, Oxycodone HCl controlled-release
- Where
- 194 sites in United States, Czechia and 2 more
- Volunteers
- 455 people
- Sponsor
- Purdue Pharma LP
Chronic Severe Pain
A Non-interventional, Observational Study for Targinact® Treatment in Patients With Chronic Severe Pain
This non-interventional, observational study is set up on request of the Belgian reimbursement authorities and evaluates the efficacy of Targinact with regard to pain relief and constipation in daily clinical practice in Belgium…
- Trial name
- NCT01710904
- Testing
- Targinact® (oxycodone/naloxone)
- Where
- Belgium
- Volunteers
- 68 people
- Sponsor
- Mundipharma CVA
Constipation
Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC)
The purpose of this study is to evaluate the safety and efficacy of a range of oral SP-333 doses for the treatment of opioid-induced constipation (OIC) in adults with non-cancer pain taking opioids.
- Trial name
- OIC (NCT01983306)
- Testing
- SP-333 1 mg, SP-333 3 mg, SP-333 6 mg
- Where
- 42 sites in United States
- Volunteers
- 292 people
- Sponsor
- Bausch Health Americas, Inc.
Opioid Induced Constipation
Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC.
This is a single-arm, open label, multinational, multicentre, prospective, real world observational study of Naloxegol in adult subjects with Opioid Induced Constipation (OIC) in patients receiving Naloxegol in routine clinical…
- Trial name
- NACASY (NCT03638440)
- Testing
- Naloxegol
- Where
- 10 sites in Denmark, Finland and 8 more
- Volunteers
- 183 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
OIC
A Prospective, Multicenter, Randomized, Parallel-controlled, Superiority Trial
This study intends to design and conduct a prospective, multicenter, randomized, parallel-controlled, superiority trial to evaluate the symptom-relieving effects of Shouhui Tongbian Capsule on opioid-induced constipation (OIC) in…
- Trial name
- NCT07534995
- Testing
- the Shouhui Tongbian Capsule, Lactulose
- Volunteers
- 270 people
- Sponsor
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Healthy, Opioid-induced Constipation
A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of TD-1211 in healthy subjects and activity in subjects with opioid-induced constipation (OIC).
- Trial name
- NCT01040637
- Testing
- TD-1211
- Where
- 3 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Glycyx Therapeutics
Bowel Dysfunction
Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction
This is a double-blind, randomized, parallel group, dose ranging study of subcutaneous methylnaltrexone to be conducted in patients with advanced medical illness and poorly controlled opioid induced constipation.
- Trial name
- NCT01367574
- Testing
- SC MNTX
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Bausch Health Americas, Inc.